With a thorough analysis of clinical data, we found that low expression levels of AGAP2-AS1 are associated with advanced FIGO stage, high histological grade, lymph node metastasis and serous histological subtype. Here, AGAP2 is linked to metastatic malignant neoplasm in the lymph nodes.